Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vintafolide versus paclitaxel, and vintafolide + paclitaxel versus paclitaxel, in folate receptor-positive advanced triple-negative breast cancer
2012-005170-65Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Jul 2013
- Modality
- Small Molecules, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vintafolide, paclitaxel in triple-negative breast cancer (TNBC), sponsored by Merck & Co.. Started Jul 2013; status: terminated.
02
Drugs
vintafolidepaclitaxel
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2012-005170-65.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005170-65.